BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables)

3 Months Ended

Dec. 31, 2023

BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES

Schedule of revenues disaggregated by business operations and timing of revenue recognition

	Three Month Period Ended:
	December 31,		December 31,
	2023		2022
Research and development services (over-time)	$	77,535	$	126,058
Clinical laboratory testing services (point-in-time)		12,120		3,074,414
Clinical laboratory testing services (over-time)		324,580		1,439,881
Product and authentication services (point-in-time):
Supply chain		467,487		411,765
Large Scale DNA Production		—		127,506
Asset marking		9,442		83,128
Total	$	891,164	$	5,262,752

Schedule of opening and closing contract balances

		October 1,		December 31,		$
	Balance sheet classification	2023		2023		change
Contract liabilities	Deferred revenue	$	270,435	$	282,034	$	11,599

Schedule of anti-dilutive securities not included computation of net loss per share

Securities that could potentially dilute basic net loss per share in the future that were not included in the computation of diluted net loss per share because to do so would have been anti-dilutive for the three-month periods ended December 31, 2023 and 2022 are as follows:

	2023	2022
Warrants	5,213,213	7,295,588
Restricted Stock Units	282,640	—
Stock options	2,189,019	1,006,141
Total	7,684,872	8,301,729